How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Consider two of the company's leading candidates in weight loss: orforglipron and retatrutide. Both medicines are in phase 3 studies, but not just as weight loss management products: They're being ...

Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug, retatrutide, say that while they have seen incredible weight loss, the trial has also come ...

Early trials of the drug, retatrutide, have already shown it can help people shed a quarter of their body weight in under a year — almost twice as effective as Ozempic. But now scientists ...

Retatrutide, produced by Eli Lilly, also activates glucagon receptors, alongside GLP-1 receptors and gastric inhibitory polypeptide (GIP) receptors, which helps regulate blood glucose and nutrient ...

But that's not all. From Eli Lilly's other recent launches, such as cancer medicine Jaypirca, to exciting pipeline candidates like Retatrutide -- a potential next-gen anti-obesity medicine -- not ...

Retatrutide is a three-drug combination from Eli Lilly that appears even more effective than tirzepatide. Last December, Novo Nordisk revealed phase 3 results for cagrisema, a combination of ...

Her weight dropped so much that researchers reduced her dose of the treatment, called retatrutide. Still, she continued to feel too nauseous, so she decided by herself to start skipping every ...

Retatrutide targets GIP and GLP-1 – the same as Lilly’s fast-growing diabetes therapy Mounjaro (tirzepatide) – but adds in activity against glucagon. That three-pronged attack helped ...

For Kristian Cook, every pizza box he opened was another door closed on the path to overcoming obesity. “I had massive cravings for pizza,” he says. “That was my biggest downfall.” ...

Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning of the coronavirus pandemic through the middle of last June, shares of ...